• Company
• Companies are ending a series of phase 3 of core R&D
• by Lee, Seok-Jun Sep 15, 2022 05:55am

• Company
• NSCLC drug Rybrevant can be prescribed at general hospitals
• by Eo, Yun-Ho Sep 15, 2022 05:55am

• Company
• JW Pharm sells ₩10 bil with Actemra in 1H 2022
• by Chon, Seung-Hyun Sep 15, 2022 05:55am

• Policy
• The flu-coronavirus outbreak has been predicted
• by Kim, Jung-Ju Sep 15, 2022 05:55am

• Company
• The NHIS signed a MOU with Viatris to manage chronic dz
• by Eo, Yun-Ho Sep 15, 2022 05:55am

• Company
• Complicated patent extension period than foreign countries
• by Kim, Jin-Gu Sep 14, 2022 05:50am

• Company
• Novartis Korea to close down Respiratory BU next month
• by Sep 14, 2022 05:50am

• Company
• Tylenol-focused sales for COVID-19-related use dispersed
• by Kim, Jin-Gu Sep 14, 2022 05:50am

• Policy
• Lowest price falls to PVA
• by Lee, Tak-Sun Sep 14, 2022 05:50am

• Company
• Novartis' application for voluntary retirement is closed
• by Sep 14, 2022 05:50am